BAD HOMBURG, GERMANY - Newsaktuell - December 6, 2019 - Fresenius Kabi held its United for Clinical Nutrition (UCN) Satellite Symposium during the 20th Congress of Parenteral and Enteral Nutrition Society of Asia (PENSA) on October 9, 2019, in Hong Kong.
Dr. Jesus Inciong (Philippines) leads a presentation on current clinical nutrition practices in Asian hospitals.
The UCN symposium gathered today's top experts to exchange insights on clinical nutrition. In photo from left to right: Prof. Seo, Dr. Ungpinitpong, Dr. Inciong, Prof. Joshi and Prof. Laviano.
The symposium's featured topic was the UCN Nutrition Insights Day Asia (NID), a comprehensive survey led by an advisory board and supported by Fresenius Kabi that provides insights into clinical nutrition practices in 83 hospitals in India, Indonesia, the Philippines, South Korea, Taiwan, Thailand and Vietnam.
Leading clinical nutrition experts were present to discuss UCN NID: Prof. Alessandro Laviano (Italy), Prof. Rajeev Joshi (India), Prof. Han-Hsui Hsu (Taiwan), Dr. Jesus Fernando B. Inciong (Philippines), Dr. Winai Ungpinitpong (Thailand), and Prof. Jeong-Meen Seo (South Korea).
As nutritional deficits continue to burden the global healthcare system, the panel of experts emphasized the importance of prioritizing patients' nutritional needs in order to effectively enhance post-admission recovery. Prof. Seo said, "The time is now. No more excuses. We must work together to bring clinical nutrition forward."
NID results will soon be available at www.unitedforclinicalnutrition.com.
About 'United for clinical nutrition'
In 2014, Fresenius Kabi established UCN to raiseawareness for disease-related malnutrition around the world. Through regionaldata collection and clinical assessment, and tailored events and tools forhealthcare professionals, UCN aims to reduce the prevalence of hospitalmalnutrition. In 2018, the initiative expanded in Asia. To learn more, visit www.unitedforclinicalnutrition.com.
Fresenius Kabi is a global healthcare company thatspecializes in lifesaving medicines and technologies for infusion, transfusionand clinical nutrition. The company's products and services are used to helpcare for critically and chronically ill patients. Fresenius Kabi's productportfolio comprises a comprehensive range of I.V. generic drugs, infusiontherapies and clinical nutrition products as well as the devices foradministering these products. In the field of biosimilars, we focus onautoimmune diseases and oncology. In 2019, the first biosimilar product byFresenius Kabi was launched. Within transfusion medicine and cell technologies,Fresenius Kabi offers products for collection and processing of blood and cellcomponents.
With its corporate philosophy of "caring forlife", the company is committed to putting essential medicines andtechnologies in the hands of people who help patients and finding the bestanswers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.